Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis.

A trend was observed between increases in ESR after 24 weeks of tofacitinib treatment and an increase in the future risk of MACE, although this did not reach statistical significance.

also in 111,027 other papers

The present study also showed a trend toward an association of elevated ESR following tofacitinib treatment with an increased risk of future MACE, and this is consistent with findings in a population‐based study of CV death, which suggested that patients with RA who have sustained elevation of ESR may have a higher risk of CV death 17 .

also in 53,322 other papers